Middle East supply disruptions drive a rebound in EM chemical stocks, but the earnings boost may last only 1-2 quarters

Overview

This report updates HSBC's supply-demand, pricing, earnings, and valuation assumptions for its covered emerging market chemical companies. The core backdrop is that the Middle East conflict caused MENA capacity losses, constrained Asian feedstocks, and delayed new capacity additions, driving a rapid short-term rebound in petrochemical prices and chemical share prices. HSBC views this change as a one-off profit shock caused by supply disruption rather than the start of a long-term cyclical upswing.

Core views

HSBC believes the most important short-term variable is whether companies can secure feedstocks and transport products to end markets. Companies with integrated, low-cost assets and feedstock and sales channels that are relatively unaffected are more likely to benefit from wider spreads. Braskem and Orbia are relatively advantaged because their operations and sales channels are less disrupted; Rabigh is seen as having room for improvement due to its west coast location and restructuring progress; although Alujain faces lower operating-rate assumptions, its debt-free balance sheet provides defense. At the same time, HSBC stresses that the earnings peak may be concentrated in 1Q and 2Q 2026, after which prices and margins may decline.

Analysis framework

The report revalues covered companies by updating supply-demand balance models, oil price assumptions, product price assumptions, operating rates, sales volumes, and company valuation models. HSBC raises its 2026 oil price assumption from USD65/b to USD80/b and, incorporating the impact of the Middle East conflict on capacity, feedstocks, and logistics, recalculates product spreads, revenue, EBITDA, net profit, and target prices.

Methodology notes

• Supply-demand analysisGlobal chemical supply-demand balance model

  Capacity losses, operating rates, and inventory drawdown

  The model assumes MENA capacity losses continue through April 2026, Asian production is constrained by feedstock limitations through the end of 2Q 2026, and new Asian capacity additions are delayed by one quarter; this leads to a derived temporary peak in global operating rates of about 110% in March/April.

• Valuation methodDCF, EV/EBITDA and NPV

  Revaluation of company target prices

  Alujain uses a DCF target price; Braskem continues to be valued at 6.8x EV/EBITDA; Rabigh uses a combined BoTB project NPV and DCF valuation; Orbia's target price is raised along with higher earnings assumptions.

• Scenario assessmentOne-off supply shock framework

  Margins earn excess profits in the short term before reverting to low levels

  HSBC believes the price and profit improvement will be concentrated mainly in 1-2 quarters, with operating rates returning to the low-80% range in the third and fourth quarters and margins reverting toward low levels before year-end; urea is identified as a possible exception with greater persistence.

Asset mapping & comparison

Structured mapping from thesis to named assets (strengths, weaknesses, peers, risks).

• Alujain (ALCO AB)

  A beneficiary of rising polypropylene spreads; Buy maintained.

  Strengths

  A debt-free balance sheet, low-cost asset base, and potential improvement in shareholder returns provide defense and recovery resilience.

  Weaknesses

  Operating-rate assumptions for Q1 and Q2 were lowered; 2026 earnings are constrained by operating rates, and normalized 2027 prices also affect longer-term earnings.

  Comparison

  Compared with the previous target price of SAR44, the new DCF target price is reduced to SAR34, but it is still above the current price of SAR28.30.

  Risks

  Operating-rate recovery slower than expected, product prices falling faster than expected, or demand weakening.

• Braskem (BRKM5 BZ)

  A relative beneficiary with less disruption to operations and end-market sales; Buy maintained.

  Strengths

  A US-sourced supply chain makes naphtha availability relatively unconstrained, allowing it to capture wider product spreads.

  Weaknesses

  Higher feedstock and logistics costs may still pass through to pricing, and the company remains in a phase of narrowing losses.

  Comparison

  Target price unchanged at BRL16; HSBC raised its 2026 revenue estimate by 12% and EBITDA estimate by 19%.

  Risks

  Higher feedstock costs, higher logistics costs, and product price corrections in 2027.

• Orbia (ORBIA* MM)

  A beneficiary with better production and sales continuity; Buy maintained.

  Strengths

  Facilities remain operational and output remains saleable, putting it in a favorable position relative to competitors in the Middle East and Asia; PVC margins improve.

  Weaknesses

  Outer-year earnings may decline as prices correct.

  Comparison

  Target price raised from MXN24 to MXN25, versus the current price of MXN21.59.

  Risks

  PVC spread contraction, cost assumptions below expectations, or weak demand.

• Rabigh (PETROR AB)

  A Buy-rated name supported by its west coast location and restructuring projects.

  Strengths

  Deleveraging has been completed, and asset upgrades plus the BoTB project provide a path for structural improvement; the stock price has risen about 48% since the conflict began.

  Weaknesses

  Historical performance has been weak, and the company is still in the process of restructuring and operational improvement.

  Comparison

  Target price reduced from SAR14 to SAR13; the BoTB project NPV is SAR4.7 and the DCF portion is SAR8.9.

  Risks

  BoTB project execution, long-term price correction, demand destruction, and persistent supply disruption.

• Tasnee / Petkim

  Reduce ratings maintained.

  Strengths

  Some price upside may improve revenue in the short term.

  Weaknesses

  HSBC has not changed its Reduce view, indicating that the risk-reward remains relatively unattractive.

  Comparison

  Relative to the Buy-rated names, the report does not emphasize equivalent advantages in feedstock or sales channels.

  Risks

  Price declines, constrained operating rates, and lack of valuation support.

Key data

• EM chemical stock performanceabout +16%Up since the start of the Middle East conflict, significantly outperforming the emerging market index, which fell 13% over the same period.
• Platts chemicals indexabout +60%Up since early March, reflecting a sharp strengthening in petrochemical benchmark prices.
• Peak global operating rateabout 110%HSBC estimates it peaked in March/April, mainly driven by a sharp inventory drawdown.
• 2026 global operating rate impactabout +500bp to about 86%The increase is mainly concentrated in 1Q and 2Q 2026.
• Oil price assumptionUSD80/bThe 2026 oil price assumption was raised from USD65/b to USD80/b.
• Alujain target priceSAR34, previously SAR44Buy maintained; 2026 revenue estimates increased, but lower operating rates and normalized 2027 prices reduce earnings forecasts.
• Braskem target priceBRL16, unchangedBuy maintained; 2026 revenue estimates raised 12%, EBITDA estimates raised 19%.
• Orbia target priceMXN25, previously MXN24Buy maintained; 2026 EBITDA and net profit estimates raised 7% and 13%, respectively.
• Rabigh target priceSAR13, previously SAR14Buy maintained; 2026 revenue and EBITDA estimates raised 30% and 24%, respectively, but lower long-term prices reduce valuation.

Impact & implications

The investment implication is that short-term trading opportunities come from price shocks, position covering, and wider spreads, but in the medium term investors need to be alert to margin normalization. Companies with advantages in feedstock access, logistics channels, and low-cost assets are better positioned to realize short-term pricing windfalls; companies in the Middle East or Asia that are more heavily disrupted may face constraints on operating rates, volumes, and logistics. If disruptions are prolonged, short-term windfall profits could also turn into demand destruction, creating a net negative for the industry.

Risks

• If Middle East disruptions last too long, short-term windfall profits could turn into demand destruction and become a net negative for the industry.
• MENA capacity losses, Asian feedstock constraints, and logistics channel risks may lead to divergence in operating rates and volumes across companies.
• If product prices correct rapidly in 2027 or earlier, long-term earnings and target prices will come under pressure.
• Higher oil prices, feedstock costs, and logistics costs may offset the spread gains from rising product prices.
• Ratings and target prices depend on a 6-12 month market realization period, and names that have already rebounded sharply may face pullback risk.

What to watch

• Whether MENA capacity losses ease after April as assumed.
• Whether Asian feedstock supply constraints persist through the end of 2Q 2026 or longer.
• Whether the Platts chemicals index and product prices such as PE, PP, PVC, MEG, and methanol remain elevated.
• Whether global operating rates fall back from about 110% in March/April to the low-80% range in the third and fourth quarters.
• Whether less-disrupted companies such as Braskem, Orbia, and Rabigh deliver on volumes, spreads, and EBITDA.
• Whether prolonged disruptions begin to cause end-demand destruction.